News

BioAtla Showcases Promising Results for Mecbotamab Vedotin in Cancer Treatment

BioAtla Showcases Promising Results for Mecbotamab Vedotin in Cancer Treatment

BioAtla Presents Groundbreaking Clinical Data for Mecbotamab Vedotin

SAN DIEGO, Oct. 3, 2025 — BioAtla, Inc. (NASDAQ: BCAB), a pioneering biotechnology firm dedicated to developing advanced biologic therapies, has announced noteworthy clinical results for its innovative antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011). This promising data will be shared at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, MD from November 5-9, 2025.

Highlighting Significant Clinical Outcomes

The presentation, titled “Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC”, will be led by Dr. Mihaela Druta from Moffitt Cancer Center on November 7, 2025. This intriguing presentation will focus on the median overall survival of patients who previously faced challenges with conventional treatments.

Mecbotamab Vedotin: A Novel Approach

Mecbotamab vedotin represents a significant advancement in cancer therapies targeting AXL, a protein linked to tumor growth and metastasis. The ongoing trials are expected to unveil the potential of this treatment to provide a new lease on life for those battling rare and aggressive forms of cancer.

Access to Presentation Materials

Following the presentation, interested parties can access a copy of the materials via the publication section of the company’s website, which will be made available after the conclusion of the talk. This accessibility underscores BioAtla's commitment to transparency and information dissemination within the medical community.

About BioAtla, Inc.

BioAtla is at the forefront of biotechnology, operating from its bases in San Diego, California, and Beijing, China. The company specializes in developing conditionally active biologics that have shown to offer higher efficacy and lower toxicity compared to traditional therapies. Its proprietary technology platform facilitates the creation of innovative monoclonal and bispecific antibodies aimed at solid tumors.

Robust Intellectual Property Portfolio

The organization boasts an impressive portfolio of over 780 active patent matters, with more than 500 patents granted globally. This extensive patent coverage secures BioAtla’s place in the market, ensuring its methodologies and products are protected across leading markets worldwide.

Company Contacts

Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945

External Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Frequently Asked Questions

What is mecbotamab vedotin?

Mecbotamab vedotin is an investigational antibody-drug conjugate targeting AXL, designed to treat various types of cancer, including soft tissue sarcomas.

When will the clinical data be presented?

The clinical data will be presented at the 2025 SITC Annual Meeting on November 7, 2025.

Who is presenting the data?

Dr. Mihaela Druta from Moffitt Cancer Center will deliver the presentation.

Why is this presentation significant?

This presentation highlights the effectiveness of mecbotamab vedotin in increasing median overall survival for patients with treatment-refractory cancers.

How can I access the presentation materials?

After the presentation concludes, you can access the materials in the publication section of BioAtla’s website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 144

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 291

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 263

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 159

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 242

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 327

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

2026 Honors Shaping Leadership Through Innovation

Updated Category News Views 52

Frost & Sullivan Institute: Leading By Example Alright, folks, we’re talking about the kind of business leadership that isn’t just about fattening the bottom line. The Frost & Sullivan Institute rolled out the carpet for companies that don’t just talk the talk—they walk the walk. This recognition isn't just another plaque for the wall; it's a pat on the back for...

Continue Reading
Boosting Franchise Performance Through Gamification with Batteries Plus

Updated Category News Views 204

Revolutionizing Franchise Excellence: The Plus Games Batteries Plus, a leader in the battery retail sector, has embarked on an exciting journey with its newly announced initiative called The Plus Games. This program is designed to transform franchisee training and sales strategies by gamifying the entire process. The objective? To cultivate exceptional performance and...

Continue Reading
Investigation into Eos Energy Enterprises' Potential Securities Fraud

Updated Category News Views 213

Investigation into Eos Energy Enterprises Pomerantz LLP is currently investigating claims concerning investors of Eos Energy Enterprises, Inc. (NASDAQ: EOSE). This inquiry raises questions about whether the company and some of its executives may have been involved in securities fraud or other fraudulent business practices. Recent Developments at Eos Energy Recently, Eos...

Continue Reading
Emerging Trends Transforming the Global Cold Brew Coffee Market

Updated Category News Views 184

Impact of Millennial Preferences on Cold Brew Coffee The cold brew coffee market is poised for significant growth, estimated to expand by USD 519.2 million within the forecast period. This growth is largely driven by changing consumer preferences, particularly among millennials who favor modern, convenient beverage choices. As more companies enter the market with...

Continue Reading
EMCOR Group, Inc. Announces Quarterly Dividend for Shareholders

Updated Category News Views 74

EMCOR Group, Inc. Announces Quarterly Cash Dividend NORWALK, Conn. - EMCOR Group, Inc. (NYSE: EME) has proudly declared a regular quarterly cash dividend of $0.25 per common share. This announcement was made by the Board of Directors, showing their ongoing commitment to delivering value to shareholders. Dividend Payment Details The scheduled payment date for the upcoming...

Continue Reading